This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

QIAGEN's CEO Hosts Investor Day - Conference Call Transcript

And this brings me now to a slide that shows our competitive landscape or at least benchmarks us against companies that we’re very often compared to. The differentiation that we as a company have is that, we basically span in all of our areas both the Life Sciences and Molecular Diagnostics. We have great and formidable competitors in the various sub-segments at the market, but there is no company, that spans the continuum from the basic research field through the development processes into routine molecular diagnostics.

Most of the companies are blank on the academic field and the diagnostic space. We’re blank on the diagnostics activities here for companies who are active in the life sciences area. That continuum will become more and more important going forward because the transitional buyer marker from clinical development into routine diagnostics is happening at a break next speed.

We’re not going to see the traditional 10 years wait, 15 years wait, we’re going to see a much faster transition of these types of techniques, and going forward, the ability to basically allow that to happen on the same platforms with the same types of technologies is going to be a true differentiator.

If you look at the various diagnostics fields that we have down, I’ll focus on that. We see the Prevention, Profiling, Personalized Healthcare, and Point of Need activities that we highlighted here. Our focus is clearly at the moment in the area of prevention and profiling in terms of sales base. But in terms of the leadership position, our position in personalized medicine is really second to none. And this is something that we will talk about in little bit more detail also in the course of this presentation. Now, so there might be some misclassifications here. It’s always very subjective, but it was – this slide was done also with some analytical support and might be of help for any analysis going forward.

7 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs